About 3DHEALS Company Directory:

3DHEALS updates this collection of public and private companies, government and non-government institutions, and any relevant research organizations in healthcare 3D printing, bioprinting, AR/VR, 3D technologies, on a weekly basis. Access to this directory is free to 3DHEALS Premium and Enterprise members. 


Add your company to 3DHEALS Directory:

(Please click the same above buttons for significant updates of your organizational information. Map is updated monthly.)

Organization Name
Headquater location

Pandorum Technologies Pvt. Ltd.

Pandorum Technologies Pvt. Ltd. is a Bangalore-based biotechnology company focusing on tissue engineering and regenerative medicine. With its distinct synergy of life science, engineering, and clinical competencies, the company designs and manufactures three-dimensional functional human tissues; intended for medical research and therapeutics

Headquarters EGF-4/5, Bangalore Bioinnovation Centre, Helix biotech park, Electronic City-1, IBAB campus Bangalore Karnataka 560100 India
Categories: Bioprinting /Biofabrication, Medical Devices, Pitch3D
CEO: Tuhin Bhowmick


Founded in 2011 by academic entrepreneurs, Pandorum Technologies Pvt. Ltd. is a Bangalore-based biotechnology company with a focus on tissue engineering and regenerative medicine. With its distinct synergy of life science, engineering, and clinical competencies, the company designs and manufactures three-dimensional functional human tissues; intended for medical research and therapeutics.

Pandorum Technologies is supported by the Biotechnology Industry Research Assistance Council, Department of Biotechnology, GoI. Pandorum’s labs are presently located in the Center for Cellular and Molecular Platforms, National Centre for Biological Sciences campus, Bengaluru, and in the Bangalore Bioinnovation Centre, Biotech Park, Electronics City Phase 1, Bengaluru.


Currently, the company seems to focus on three areas: Cornea, Liver, Lung

Bioengineered Liquid Cornea

The company’s hydrogel formulation has 3 major components. Two biopolymers undergo a photoactive mediated transition from the liquid phase to a hydrogel or semi-solid phase, where it takes the exact shape to perfectly fill in the wound site. The composition is biomimetic in light transmittance and provides adequate mechanical support. The bioengineered liquid cornea is a regenerative treatment and this biopolymer acts as a sacrificial matrix for accelerating the growth of host tissue to cover the wound site. The trigger for this growth is provided by a bioactive component, the exosomes delivered to the wound site, embedded in the biopolymeric matrix. These exosomes are derived from the population of predominant cell types in the cornea. They are programmed to promote scarless wound healing, to restore vision, the primary function of the cornea and eye.

Currently, Pandorum is performing pre-clinical animal trials and aiming toward human clinical trials.


Bioengineered Corneal Lenticule

Corneal transplantation is not a viable option for Keratoconus (thinning and bulging out of cornea) and keratitis (inflammation in the cornea), which are the two most common problems. This treatment strategy has a downside such as a shortage of clinical-grade donor corneas, and post-transplant complications, including rejection and infections. Pandorum’s efforts have been focused on developing bio-engineered corneal lenticule which can aid in overcoming the challenges of corneal transplantation.

A unique combination of biopolymer (bio-ink) based corneal lenticule mimicking the shape and size of the human cornea which is fabricated using additive manufacturing technology. The corneal lenticule would possess all the desired physical and biological properties necessary for long-term integration with the host tissue while supporting steady regeneration. Currently, the technology platform is being optimized for obtaining effective treatment for various corneal blindness conditions. Meanwhile, advanced-stage in-vitro validation of bio-ink is being carried out.

3D Liver Tissue: Organoids, Spheroids, Tissue

Drug metabolism and pharmacokinetics (DMPK) has become one of the core disciplines in the drug discovery process that focuses on evaluating the safety and efficacy of the drug candidates. Sub-optimal DMPK profile has been one of the major reasons for the attrition of drugs at the clinical phase of the trial indicating the poor ADME properties (Absorption, Digestion, Metabolism, and Excretion) and drug-drug interaction (DDI). Our 3D hepatocyte spheroids are suitable for long-term culture with enhanced hepatocyte phenotypes like albumin secretion, and CYP activity for testing drug-induced toxicity and metabolism.
Pandorum’s 3D organoids containing multi-lineage cell types recapitulate the native microenvironment with parenchymal hepatocytes co-cultured with kupffer cells, hepatic stellate cells, and liver endothelial cells. These organoids are induced to recapitulate the complex disease phenotype including steatosis, inflammation, and fibrosis involving multiple cell-cell cross-talks. The above model would mimic the in-vivo disease physiology and thus increases the accurate prediction of drug effect during NASH drug discovery. Our organoid model is suitable for long-term culture with more than two weeks of assay window for the dosing of potential anti-steatosis, anti-inflammatory, and anti-fibrotic drugs
3D cultured organoids are not only emerging as the platform for drug screening and disease modeling but also have potential in regenerative medicine and therapy. Pandorum aims to develop 3D bio-printed vascularized mini-organ or organ patches with the potential of engrafting onto the host tissue upon transplantation. Currently, the company is developing a  prototype for the same.

Lung tissue

Since the outbreak of COVID-19, Pandorum has been expanding its reach by further developing the exosome platform, particularly for the post COVID19 trauma. Exosome therapy is a cell-free therapy and with the manifestation of the defined set of cargo, healing of lung tissue in COVID-19 patients could be easier. In this therapy, exosomes packed with immuno-modulatory, anti-fibrotic factors could alleviate the pain, inflammation, and pulmonary fibrosis which will lead to tissue repair. Unlike conventional therapeutic strategies, their physiochemical stability in the body and multidimensional packaging significantly reduces the risk of adverse effects and provides a cell-free regenerative medicine.

Pandorum’s Approach: The generation of therapeutic-grade extracellular vesicles (EVs) with specific cargo-loaded proteins is the principal objective for the treatment of regenerative therapy. Scalable MSCs expansion with an optimized culture condition to select therapeutically enriched EVs is in progress for developing the proprietary Pandorum technology platform.